Vaccination with immuno-isolated cells producing an immunomodulator
The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunization in humans and animals. These cells can be used for vaccination where they provide the immunomodulator in an active form, in a continuous, non-immunogenic manner in the immediate vicinity of the vaccine antigen(s). The invention also relates to a vaccine composition comprising immuno-protected encapsulated cells producing an immunomodulator and an antigenic component. The invention also relates to a kit comprising a cell as described and an antigenic component. The strategy of the invention is perfectly suited for both cancer immunotherapy and vaccination against infectious agents.
1. A vaccine composition comprising two components:
a) a first component comprising at least one macrocapsule comprising between 2×10 5 and 5×10 7 immuno-isolated allogeneic human cells that secrete at least 10 ng/24 hours of an immunostimulatory agent for at least 5 to 7 days, wherein the immunostimulatory agent is GM-CSF and wherein the macrocapsule is retrievable; and
b) a second antigenic component comprising a population of tumour cells from the patient to be treated, wherein said tumour cells are irradiated to prevent growth of said tumor cells.
2. The vaccine of claim 1 , wherein said immuno-isolated cells further produce another immunostimulatory agent.
3. The vaccine of claim 2 , wherein said second immunostimulatory agent is selected from the group consisting of IL-12, IL-15, IL-4, Interferon gamma, chemokines, and dendritic growth factors.
4. The vaccine of claim 1 , wherein said macrocapsule is selectively permeable.
5. The vaccine of claim 4 , wherein said macrocapsule is selectively permeable to molecules with molecular weight smaller than 280 kDa.
6. The vaccine of claim 1 , wherein said immuno-isolated cells are genetically modified to express the immunostimulatory agent.
7. The vaccine of claim 6 , wherein the genetic modification is achieved by transfection by a plasmid or infection by a virus.
8. The vaccine of claim 1 , wherein said immuno-isolated cells are a human established cell line selected from the group consisting of a fibroblast and an epithelial cell line.
9. The vaccine of claim 1 , wherein said immuno-isolated cells are immortal or immortalised.
10. The vaccine of claim 1 , wherein said immuno-isolated cells are non-tumoral.
11. The vaccine of claim 1 , wherein the immuno-isolated allogeneic human cells that secrete between 500 and 1000 ng/24 hours of the immunostimulatory agent.
12. A pharmaceutical composition comprising the vaccine of claim 1 and a physiologically acceptable carrier.
13. A kit comprising the vaccine of claim 1 .
14. A method for treating or preventing cancer in a patient suffering therefrom, the method comprising administering the vaccine according to claim 1 to the patient.
15. The method according to claim 14 , wherein said vaccine is to be implanted and subsequently removed.
16. The method according to claim 15 , wherein removal is accomplished between 2 to 7 days after implantation.
17. The method of claim 16 , wherein removal is accomplished between 5 to 7 days after implantation.